XLRN
Acceleron Pharma Inc. [XLRN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XLRN Stock Summary
In the News
XLRN Financial details
Company Rating
Buy
Market Cap
0
Income
-254.85M
Revenue
112.76M
Book val./share
11.79
Cash/share
9.69
Dividend
-
Dividend %
-
Employees
312
Optionable
No
Shortable
Yes
Earnings
04 Nov 2021
P/E
-61.15
Forward P/E
-
PEG
-7.95
P/S
-
P/B
11.87
P/C
18.45
P/FCF
-
Quick Ratio
14.56
Current Ratio
14.85
Debt / Equity
0.03
LT Debt / Equity
0.02
-
-
EPS (TTM)
-4.21
EPS next Y
-
EPS next Q
-
EPS this Y
22.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.95%
Revenue last 5Y
27.21%
Revenue Q/Q
22.4%
EPS Q/Q
10.48%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
1%
ROA
-18%
ROE
-25%
ROC
-0.19%
Gross Margin
-
Oper. Margin
-181%
Profit Margin
-179%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
177.2-179.85
52W High
-0.14%
52W Low
+0.99%
RSI
-
Rel Volume
6.23
Avg Volume
1.27M
Volume
7.88M
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.131428
-
-
Volatility
0%, 0%
Prev Close
0%
Price
178.75
Change
0.87%
XLRN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.74 | 0.33 | 0.3 | 1.41 | 1.63 | |
| Net income per share | -1.52 | -2.68 | -2.59 | -2.38 | -2.92 | |
| Operating cash flow per share | -1.19 | -1.9 | -2.06 | -1.79 | -2.29 | |
| Free cash flow per share | -1.28 | -2.01 | -2.12 | -1.85 | -2.37 | |
| Cash per share | 3.73 | 6.86 | 6.35 | 8.22 | 14.96 | |
| Book value per share | 6.03 | 9.04 | 6.36 | 8.57 | 15.05 | |
| Tangible book value per share | 6.03 | 9.04 | 6.36 | 8.57 | 15.05 | |
| Share holders equity per share | 6.03 | 9.04 | 6.36 | 8.57 | 15.05 | |
| Interest debt per share | 0 | 0 | 0 | 0.62 | 0.12 | |
| Market cap | 955.21M | 1.72B | 2B | 2.78B | 7.27B | |
| Enterprise value | 934.26M | 1.62B | 1.85B | 2.58B | 6.62B | |
| P/E ratio | -16.75 | -15.82 | -16.82 | -22.27 | -43.77 | |
| Price to sales ratio | 34.4 | 127.25 | 142.87 | 37.59 | 78.54 | |
| POCF ratio | -21.37 | -22.36 | -21.11 | -29.65 | -55.76 | |
| PFCF ratio | -19.87 | -21.15 | -20.54 | -28.64 | -54.02 | |
| P/B Ratio | 4.23 | 4.7 | 6.84 | 6.19 | 8.5 | |
| PTB ratio | 4.23 | 4.7 | 6.84 | 6.19 | 8.5 | |
| EV to sales | 33.64 | 119.82 | 132.57 | 34.81 | 71.55 | |
| Enterprise value over EBITDA | -16.89 | -15.3 | -16.11 | -21.29 | -40.82 | |
| EV to operating cash flow | -20.9 | -21.05 | -19.58 | -27.46 | -50.8 | |
| EV to free cash flow | -19.43 | -19.91 | -19.06 | -26.53 | -49.21 | |
| Earnings yield | -0.06 | -0.06 | -0.06 | -0.04 | -0.02 | |
| Free cash flow yield | -0.05 | -0.05 | -0.05 | -0.03 | -0.02 | |
| Debt to equity | 0 | 0 | 0 | 0.07 | 0.01 | |
| Debt to assets | 0 | 0 | 0 | 0.06 | 0.01 | |
| Net debt to EBITDA | 0.38 | 0.95 | 1.25 | 1.7 | 3.99 | |
| Current ratio | 9.09 | 17.03 | 16.18 | 13.48 | 14.85 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.78 | 0.71 | 0.8 | 0.75 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.91 | 2.5 | 2.47 | 0 | 0 | |
| Research and developement to revenue | 2.47 | 6.66 | 7.43 | 2.08 | 1.88 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.08 | 0.06 | 0.03 | 0.04 | 0.03 | |
| Capex to revenue | -0.12 | -0.33 | -0.19 | -0.04 | -0.05 | |
| Capex to depreciation | -2.02 | -1.56 | -0.69 | -0.83 | -1.09 | |
| Stock based compensation to revenue | 0.67 | 2.1 | 1.76 | 0.31 | 0.33 | |
| Graham number | 14.37 | 23.36 | 19.26 | 21.42 | 31.47 | |
| ROIC | -0.29 | -0.3 | -0.43 | -0.27 | -0.19 | |
| Return on tangible assets | -0.23 | -0.28 | -0.38 | -0.25 | -0.18 | |
| Graham Net | 3.21 | 6.33 | 5.97 | 7.29 | 13.95 | |
| Working capital | 130.64M | 268.5M | 287.1M | 416.54M | 833.11M | |
| Tangible asset value | 225.6M | 365.22M | 292.04M | 449.48M | 855.11M | |
| Net current asset value | 124.74M | 261.28M | 283.23M | 394.49M | 816.04M | |
| Invested capital | 0 | 0 | 0 | 0.07 | 0.01 | |
| Average receivables | 3.43M | 3.4M | 5.3M | 7.79M | 17.32M | |
| Average payables | 1.23M | 1.34M | 752.5K | 1.36M | 5.38M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 42.51 | 96.66 | 183.63 | 42.16 | 102.97 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 8.59 | 3.78 | 1.99 | 8.66 | 3.54 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.25 | -0.3 | -0.41 | -0.28 | -0.19 | |
| Capex per share | -0.09 | -0.11 | -0.06 | -0.06 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
| Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.38 | 0.43 | 0.41 | 0.46 | 0.56 | |
| Net income per share | -0.66 | -0.95 | -1.05 | -1.05 | -1.16 | |
| Operating cash flow per share | -0.05 | -0.63 | -1.12 | -1.39 | -1.16 | |
| Free cash flow per share | -0.06 | -0.65 | -1.14 | -1.41 | -1.2 | |
| Cash per share | 14.79 | 14.1 | 11.34 | 10.27 | 9.69 | |
| Book value per share | 15.01 | 14.19 | 13.38 | 12.57 | 11.79 | |
| Tangible book value per share | 15.01 | 14.19 | 13.38 | 12.57 | 11.79 | |
| Share holders equity per share | 15.01 | 14.19 | 13.38 | 12.57 | 11.79 | |
| Interest debt per share | 0.11 | 0.12 | 0.12 | 0.34 | 0.33 | |
| Market cap | 6.71B | 7.71B | 8.22B | 7.62B | 10.49B | |
| Enterprise value | 6B | 7.06B | 7.78B | 7.3B | 10.17B | |
| P/E ratio | -42.75 | -33.59 | -32.36 | -29.99 | -37.21 | |
| Price to sales ratio | 297.47 | 298.09 | 331.82 | 272.74 | 306.65 | |
| POCF ratio | -2.4K | -202.22 | -120.95 | -90.27 | -147.94 | |
| PFCF ratio | -1.82K | -197.56 | -119.33 | -89.25 | -143.08 | |
| P/B Ratio | 7.5 | 9.02 | 10.13 | 9.99 | 14.6 | |
| PTB ratio | 7.5 | 9.02 | 10.13 | 9.99 | 14.6 | |
| EV to sales | 266.1 | 273.09 | 314.32 | 261.45 | 297.4 | |
| Enterprise value over EBITDA | -156.62 | -125.24 | -124.63 | -116.92 | -146.79 | |
| EV to operating cash flow | -2.15K | -185.26 | -114.57 | -86.53 | -143.48 | |
| EV to free cash flow | -1.63K | -180.99 | -113.04 | -85.55 | -138.76 | |
| Earnings yield | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Free cash flow yield | 0 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | |
| Net debt to EBITDA | 18.47 | 11.47 | 6.94 | 5.05 | 4.57 | |
| Current ratio | 24.5 | 14.85 | 14.81 | 12.07 | 12.14 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.07 | 0.66 | 1.07 | 1.33 | 1.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.81 | 2.21 | 2.31 | 2.01 | 1.75 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.32 | 0.02 | 0.01 | 0.01 | 0.03 | |
| Capex to revenue | -0.04 | -0.03 | -0.04 | -0.03 | -0.07 | |
| Capex to depreciation | -0.98 | -0.9 | -0.9 | -0.94 | -2.08 | |
| Stock based compensation to revenue | 0.35 | 0.33 | 0.63 | 0.48 | 0.33 | |
| Graham number | 14.91 | 17.44 | 17.76 | 17.2 | 17.51 | |
| ROIC | -0.04 | -0.06 | -0.08 | -0.08 | -0.09 | |
| Return on tangible assets | -0.04 | -0.06 | -0.07 | -0.08 | -0.09 | |
| Graham Net | 14.2 | 13.15 | 10.58 | 9.43 | 8.99 | |
| Working capital | 876.48M | 833.11M | 687.79M | 658.3M | 639.24M | |
| Tangible asset value | 895.14M | 855.11M | 810.83M | 763.03M | 718.15M | |
| Net current asset value | 861.15M | 816.04M | 672.65M | 644.76M | 626.91M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | |
| Average receivables | 31.16M | 24.33M | 25.65M | 27.46M | 32.69M | |
| Average payables | 10.89M | 8.67M | 6.47M | 6.95M | 7.26M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 90 | 90.81 | 91.63 | 95.73 | 93.86 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1 | 0.99 | 0.98 | 0.94 | 0.96 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.04 | -0.07 | -0.08 | -0.08 | -0.1 | |
| Capex per share | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 |
XLRN Frequently Asked Questions
What is Acceleron Pharma Inc. stock symbol ?
Acceleron Pharma Inc. is a US stock , located in Cambridge of Massachusetts and trading under the symbol XLRN
What is Acceleron Pharma Inc. stock quote today ?
Acceleron Pharma Inc. stock price is $178.75 today.
Is Acceleron Pharma Inc. stock public?
Yes, Acceleron Pharma Inc. is a publicly traded company.
Company Profile
- Volume Average 1.27M
- Employee 312
- CEO Mr. Habib Dable
- Headquarters Cambridge,MASSACHUSETTS,US
- IPO Date 2013-09-18
-
Website
http://www.acceleronpharma.com 
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
